A new trading day began on Monday, with Pyxis Oncology Inc (NASDAQ: PYXS) stock price up 3.53% from the previous day of trading, before settling in for the closing price of $1.70. PYXS’s price has ranged from $1.49 to $6.85 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 41.34%. With a float of $41.13 million, this company’s outstanding shares have now reached $59.45 million.
Let’s look at the performance matrix of the company that is accounted for 50 employees. In terms of profitability, gross margin is 84.98%, operating margin of -343.24%, and the pretax margin is -293.15%.
Pyxis Oncology Inc (PYXS) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Pyxis Oncology Inc is 30.83%, while institutional ownership is 54.02%. The most recent insider transaction that took place on Nov 26 ’24, was worth 174,364. In this transaction CFO & COO of this company bought 88,850 shares at a rate of $1.96, taking the stock ownership to the 1,199,143 shares.
Pyxis Oncology Inc (PYXS) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.33 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 41.34% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 34.60% during the next five years compared to -118.72% drop over the previous five years of trading.
Pyxis Oncology Inc (NASDAQ: PYXS) Trading Performance Indicators
Here are Pyxis Oncology Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.33. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.52.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.05, a number that is poised to hit -0.32 in the next quarter and is forecasted to reach -1.30 in one year’s time.
Technical Analysis of Pyxis Oncology Inc (PYXS)
Pyxis Oncology Inc (NASDAQ: PYXS) saw its 5-day average volume 0.82 million, a positive change from its year-to-date volume of 0.65 million. As of the previous 9 days, the stock’s Stochastic %D was 85.70%. Additionally, its Average True Range was 0.16.
During the past 100 days, Pyxis Oncology Inc’s (PYXS) raw stochastic average was set at 6.92%, which indicates a significant decrease from 93.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 68.21% in the past 14 days, which was lower than the 117.50% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.6396, while its 200-day Moving Average is $3.5173. Nevertheless, the first resistance level for the watch stands at $1.8000 in the near term. At $1.8400, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.9000. If the price goes on to break the first support level at $1.7000, it is likely to go to the next support level at $1.6400. The third support level lies at $1.6000 if the price breaches the second support level.
Pyxis Oncology Inc (NASDAQ: PYXS) Key Stats
With a market capitalization of 105.28 million, the company has a total of 59,466K Shares Outstanding. Currently, annual sales are 0 K while annual income is -73,790 K. The company’s previous quarter sales were 0 K while its latest quarter income was -17,300 K.
